PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAtazanavir
Reyataz(atazanavir)
Atazanavir, Evotaz, Reyataz (atazanavir) is a small molecule pharmaceutical. Atazanavir was first approved as Reyataz on 2003-06-20. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
BMS
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Atazanavir, Reyataz (discontinued: Atazanavir, Reyataz)
Combinations
Evotaz
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atazanavir sulfate
Tradename
Company
Number
Date
Products
REYATAZBristol Myers SquibbN-021567 RX2003-06-20
2 products, RLD
REYATAZBristol Myers SquibbN-206352 RX2014-06-02
1 products, RLD, RS
Show 1 discontinued
Atazanavir sulfate
+
Cobicistat
Tradename
Company
Number
Date
Products
EVOTAZBristol Myers SquibbN-206353 RX2015-01-29
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
atazanavirANDA2025-03-17
atazanavir sulfateANDA2025-01-24
evotazNew Drug Application2023-05-12
reyatazNew Drug Application2023-11-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acquired immunodeficiency syndromeEFO_0000765D000163B20
hiv infectionsEFO_0000764D015658B20
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Atazanavir Sulfate / Cobicistat, Evotaz, Bristol
100397182032-10-06DP
81483742029-09-03DS, DPU-1279
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AE: Protease inhibitors, direct acting antivirals
— J05AE08: Atazanavir
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR15: Atazanavir and cobicistat
— J05AR23: Atazanavir and ritonavir
HCPCS
No data
Clinical
Clinical Trials
248 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAtazanavir
INNatazanavir
Description
Atazanavir is a heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV). It has a role as an antiviral drug and a HIV protease inhibitor.
Classification
Small molecule
Drug classantivirals: HIV protease inhibitors (saquinavir type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
Identifiers
PDB—
CAS-ID198904-31-3
RxCUI—
ChEMBL IDCHEMBL1163
ChEBI ID37924
PubChem CID148192
DrugBankDB01072
UNII IDQZU4H47A3S (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Reyataz – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Atazanavir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,034 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atazanavir
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
14,186 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use